Women surveyed about their treatment for hyperemesis gravidarum, a severe form of nausea and vomiting during pregnancy, reported delayed or missed diagnoses, inadequate clinician knowledge of treatment guidelines, denied or discontinued medicines, and structural barriers restricting access to appropriate care. The qualitative study of 189 women, published in the Journal of Pharmacy Practice and Research, found that these experiences accompanied enduring emotional and psychological effects, including anxiety and post-traumatic stress syndrome. Associate Professor Luke Grzeskowiak, who led the research team at Flinders University, said the condition affects almost 4% of pregnancies.

The survey identified several issues affecting how hyperemesis gravidarum is recognised and treated. Participants described clinicians who lacked suitable training to diagnose the condition and who were either unaware of clinical management guidelines or did not follow them. Some women said they were not diagnosed with hyperemesis gravidarum when they should have been, while others reported receiving a diagnosis only late in the course of their illness. Other participants said health professionals denied prescribing or dispensing medications. The researchers also identified educational and financial status as possible influences on treatment outcomes, together with systemic barriers within Australia’s healthcare system.

Misinformation about medicine safety further disrupted care for some participants. Some women said they stopped taking medication after reading reported safety concerns that the researchers said were not aligned with current research and management guidelines. Participants also described poor management of medication side effects, including constipation and mood disorders. Current treatment focuses on supportive care and on medicines, including antiemetics, that address nausea and vomiting. Nevertheless, women reported that their symptoms were often not taken seriously and that clinicians in several professions commonly lacked appropriate education and training to recognise and manage hyperemesis gravidarum.

The study documented emotional and psychological effects during and after the illness. Participants cited impaired quality of life, anxiety and post-traumatic stress syndrome. The researchers said some women reported that hyperemesis gravidarum influenced their decision to terminate an otherwise wanted pregnancy, while others said the trauma of a previous episode left them afraid to consider another pregnancy. Collectively, the researchers proposed improving experiences and outcomes through better education for health practitioners, greater public awareness, clearer clinical practice guidelines, expanded outpatient care, investment in specialist hyperemesis gravidarum clinics and services, changes to the Pharmaceutical Benefits Scheme, and strategies to improve medicine availability and affordability. Because the research was a qualitative survey based on reported experiences and perceptions, it does not quantify how frequently these barriers occur among all pregnancies affected by the condition.

Subject of Research: Women’s experiences of pharmacological care for hyperemesis gravidarum

Article Title: Greater access to help needed for women with nausea during pregnancy

Article References: Greater access to help needed for women with nausea during pregnancy. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: hyperemesis gravidarum, pregnancy, nausea and vomiting, antiemetic medicines, qualitative survey, clinical guidelines, healthcare access, medication safety, mental health, Greater, access, help

Systematic Reviews and Meta-Analyses Face a Data Transparency Crisis Impacting Healthcare and Policy

Systematic reviews and meta-analyses occupy a cornerstone role in modern healthcare research by aggregating data from multiple studies to distill the most robust evidence possible. Their findings inform clinical guidelines, shape public health policies, and direct future research priorities. Yet, despite their importance, a troubling crisis in data transparency threatens to erode the reliability of these comprehensive syntheses. Recent research from Karolinska Institutet sheds new light on this issue, revealing that limited access to underlying raw data severely undermines the trustworthiness of meta-analytical conclusions, with potentially profound implications for healthcare decision-making.

Meta-analyses are designed to combine data across various independent studies, increasing statistical power and improving estimates of treatment effects or associations within populations. Ideally, such analyses rely on access to raw participant-level data, which allows for complex and nuanced re-analyses that can account for heterogeneity, detect biases, and evaluate assumptions. However, researchers frequently find themselves constrained by incomplete, aggregate-level summaries published in original study reports. This forces analysts to perform calculations and imputations on limited detail, often based on unverified assumptions, which can skew the meta-analytic results in subtle but consequential ways.

The problem of withholding or failing to share raw data remains pervasive despite clear mandates from many scientific journals and funding agencies that promote open data as a standard for transparency and reproducibility. Studies have repeatedly documented a discrepancy between researchers’ stated intentions to share data and the reality of actual data availability. Researchers committing to data sharing during publication seldom follow through, leaving meta-analysts reliant on summary statistics, which inherently lack the granularity needed to fully validate or challenge reported outcomes. This shortfall reverberates through the entire evidence synthesis process.

In a policy forum article featured in PLOS Medicine, Saul Martin Rodriguez and colleagues at the Department of Laboratory Medicine, Karolinska Institutet, systematically explore the ramifications of this data transparency gap. They caution that the inability to access full datasets produces opaque analyses that complicate efforts to verify findings, reproduce studies, or understand underlying methodological nuances. These barriers undermine critical scientific values—reliability, transparency, and verification—and potentially distort clinical and policy decisions that depend on synthesized evidence.

Historical precedents illustrate the danger of insufficient data access. The researchers specifically highlight hormone therapy for menopausal women, a high-profile instance where early meta-analyses, based on limited shared data, initially obscured risks associated with treatment. Only when detailed patient-level datasets eventually became available did the scientific community obtain a clearer, more accurate picture of the therapy’s adverse effects. This breakthrough recalibration led directly to amended medical guidelines, demonstrating how transparency can correct flawed understandings and safeguard public health.

Addressing the transparency crisis requires not only technical mandates but also cultural transformation within the research community. Enforcement of data sharing policies must be designed with consideration for ethical and legal constraints, such as patient privacy and intellectual property concerns. Moreover, the authors insist that transparency initiatives go beyond administrative checklists to fostering an environment where sharing data is recognized as a fundamental responsibility integral to research integrity.

Martin Rodriguez emphasizes that beyond the mechanics, transparency is a manifestation of scientific accountability. The trustworthiness of research—and by extension public trust in science—depends on open access to the underlying evidence. When data remain inaccessible, confidence erodes, and the risk of misguided healthcare interventions increases. Increasing openness mitigates these risks by enabling detailed scrutiny, replication efforts, and secondary analyses that can catch errors or biases earlier and more effectively.

The research article also identifies systemic obstacles impeding data availability, ranging from inadequate incentives for researchers to share, logistical burdens of data preparation, to concerns over misuse or misinterpretation of shared data. Addressing these challenges will require coordinated action from funding bodies, publishers, institutions, and researchers themselves to create infrastructure, reward systems, and legal frameworks that facilitate ethical and practical data sharing.

Collaboration with expert stakeholders, such as Professor David Moher of the Centre for Journalology, has strengthened the article’s recommendations by drawing on established expertise in publication science and open research practices. Their joint insights offer concrete pathways for reforming meta-analytic methodology and promote strategies to leverage systematic reviews as truly transparent syntheses that can reliably guide healthcare policies.

This deep dive into data transparency exposes a critical vulnerability in the foundation of evidence-based medicine. The widespread lack of accessible underlying data in meta-analyses risks perpetuating incomplete or misleading conclusions with real-world consequences on patient care and resource allocation. Rectifying this crisis is imperative to uphold the scientific rigor and societal trust essential for advancing human health.

The article’s publication comes at a time when open science ideals are gaining momentum worldwide. It presents a timely call to action that the scientific community must embrace if systematic reviews and meta-analyses are to fulfill their promise as gold standards of research evidence. By enforcing and normalizing comprehensive data sharing, researchers can drive greater accuracy, reproducibility, and ultimately, better health outcomes for populations globally.

Subject of Research: Data transparency issues in systematic reviews and meta-analyses and their impact on healthcare decision-making
Article Title: The data transparency crisis in research: Lessons from systematic reviews and meta-analyses
News Publication Date: 16-Jun-2026
Web References: https://doi.org/10.1371/journal.pmed.1005145
Image Credits: Photo by Karolinska Institutet